Motor complications in Parkinson's disease: Striatal molecular and electrophysiological mechanisms of dyskinesias (Q47344907)

14 January 2018

http://europepmc.org/abstract/MED/29219207

review article

1 reference

title

Motor complications in Parkinson's disease: Striatal molecular and electrophysiological mechanisms of dyskinesias (English)

1 reference

14 January 2018

http://europepmc.org/abstract/MED/29219207

1 reference

1 reference

1 reference

1 reference

Barbara Picconi

1

1 reference

14 January 2018

http://europepmc.org/abstract/MED/29219207

Ledia F Hernández

series ordinal

2

1 reference

14 January 2018

http://europepmc.org/abstract/MED/29219207

Jose A Obeso

series ordinal

3

1 reference

14 January 2018

http://europepmc.org/abstract/MED/29219207

Paolo Calabresi

series ordinal

4

1 reference

14 January 2018

http://europepmc.org/abstract/MED/29219207

language of work or name

English

0 references

publication date

8 December 2017

1 reference

14 January 2018

http://europepmc.org/abstract/MED/29219207

published in

Movement Disorders

1 reference

14 January 2018

http://europepmc.org/abstract/MED/29219207

cites work

L-3,4-dihydroxyphenylalanine-induced hypersensitivity simulating features of denervation

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Complicated response fluctuations in Parkinson's disease: response to intravenous infusion of levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Levodopa and the progression of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurons and their physiological sequelae

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

NMDA receptor GluN2A/GluN2B subunit ratio as synaptic trait of levodopa-induced dyskinesias: from experimental models to patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Neuropeptide messenger RNA expression in the 6-hydroxydopamine-lesioned rat striatum reinnervated by fetal dopaminergic transplants: differential effects of the grafts on preproenkephalin, preprotachykinin and prodynorphin messenger RNA levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Dopaminergic regulation of glutamic acid decarboxylase mRNA expression and GABA release in the striatum: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

The neostriatal mosaic: multiple levels of compartmental organization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Induction of a long-lasting AP-1 complex composed of altered Fos-like proteins in brain by chronic cocaine and other chronic treatments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Parkinson's disease: levodopa-induced dyskinesia and signal transduction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Persistent increase in olfactory type G-protein alpha subunit levels may underlie D1 receptor functional hypersensitivity in Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Regulation of the phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D1, dopamine D2, and adenosine A2A receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Lack of depotentiation at basal ganglia output neurons in PD patients with levodopa-induced dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Abnormal bidirectional plasticity-like effects in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Chronic cocaine prevents depotentiation at corticostriatal synapses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

A Role for Mitogen- and Stress-Activated Kinase 1 in L-DOPA-Induced Dyskinesia and ∆FosB Expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Parsing molecular and behavioral effects of cocaine in mitogen- and stress-activated protein kinase-1-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

MAPK cascade signalling and synaptic plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Hyperkinetic disorders and loss of synaptic downscaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Derangement of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) and extracellular signal-regulated kinase (ERK) dependent striatal plasticity in L-DOPA-induced dyskinesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

L-DOPA Oppositely Regulates Synaptic Strength and Spine Morphology in D1 and D2 Striatal Projection Neurons in Dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Nonaminergic striatal neurons convert exogenous l-dopa to dopamine in parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Buspirone in the treatment of levodopa induced dyskinesias

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Activation of 5-HT(1A) but not 5-HT(1B) receptors attenuates an increase in extracellular dopamine derived from exogenously administered L-DOPA in the striatum with nigrostriatal denervation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

MDMA and fenfluramine reduce L-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Morphological changes in serotoninergic neurites in the striatum and globus pallidus in levodopa primed MPTP treated common marmosets with dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia: Behavioral, molecular, and synaptic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Eltoprazine prevents levodopa-induced dyskinesias by reducing striatal glutamate and direct pathway activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Serotonin-to-dopamine transporter ratios in Parkinson disease: Relevance for dyskinesias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: effects of combined treatment and possible mechanisms of action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Gene therapy blockade of dorsal striatal p11 improves motor function and dyskinesia in parkinsonian mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Glutamatergic influences on the basal ganglia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Molecular basis of NMDA receptor functional diversity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Metabotropic glutamate receptors as therapeutic targets in Parkinson's disease: An update from the last 5 years of research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Metabotropic glutamate receptors in the basal ganglia motor circuit

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Effect of L-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Metabotropic glutamate receptor type 5 in levodopa-induced motor complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Investigation on tolerance development to subchronic blockade of mGluR5 in models of learning, anxiety, and levodopa-induced dyskinesia in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Striatal activation by optogenetics induces dyskinesias in the 6-hydroxydopamine rat model of Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FMDS.27261

21 January 2018

Identifiers

DOI

10.1002/MDS.27261

1 reference

14 January 2018

http://europepmc.org/abstract/MED/29219207

1 reference

14 January 2018